Teva Pharmaceuticals will partner with Syqe Medical Ltd to market a medical cannabis inhaler in Israel that is designed to treat pain without getting patients high.
The device, which is similar in appearance to a futuristic asthma inhaler, delivers precise doses, potentially resolving one of doctors’ main complaints regarding medical marijuana: the lack of certainty about how much a patient should take, how often and in what form – not to mention how much they will consume in practice, when left to their own devices.
Syqe bills its inhaler as allowing patients “to reach the coveted optimum balance between symptom relief and psychoactivity.” It has developed a “Patient Monitoring Terminal” where doctors can project the effects of given doses over time. A version of the inhaler designed for hospital use has already been employed at Rambam Hospital in Haifa for over a year.
